ATE286897T1 - Morpholinderivate als antagonisten an orexinrezeptoren - Google Patents

Morpholinderivate als antagonisten an orexinrezeptoren

Info

Publication number
ATE286897T1
ATE286897T1 AT01994716T AT01994716T ATE286897T1 AT E286897 T1 ATE286897 T1 AT E286897T1 AT 01994716 T AT01994716 T AT 01994716T AT 01994716 T AT01994716 T AT 01994716T AT E286897 T1 ATE286897 T1 AT E286897T1
Authority
AT
Austria
Prior art keywords
antagonists
morpholine derivatives
orexin receptors
orexin
receptors
Prior art date
Application number
AT01994716T
Other languages
German (de)
English (en)
Inventor
Clive Leslie Branch
Christopher Norbert Johnson
Alexander B Smith
Geoffrey Stemp
Kevin Thewlis
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0028955A external-priority patent/GB0028955D0/en
Priority claimed from GB0114291A external-priority patent/GB0114291D0/en
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Application granted granted Critical
Publication of ATE286897T1 publication Critical patent/ATE286897T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT01994716T 2000-11-28 2001-11-22 Morpholinderivate als antagonisten an orexinrezeptoren ATE286897T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0028955A GB0028955D0 (en) 2000-11-28 2000-11-28 Compounds
GB0114291A GB0114291D0 (en) 2001-06-12 2001-06-12 Compounds
PCT/EP2001/013687 WO2002044172A1 (en) 2000-11-28 2001-11-22 Morpholine derivatives as antagonists of orexin receptors

Publications (1)

Publication Number Publication Date
ATE286897T1 true ATE286897T1 (de) 2005-01-15

Family

ID=26245341

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01994716T ATE286897T1 (de) 2000-11-28 2001-11-22 Morpholinderivate als antagonisten an orexinrezeptoren

Country Status (8)

Country Link
US (1) US6943160B2 (enExample)
EP (1) EP1353918B1 (enExample)
JP (1) JP4246490B2 (enExample)
AT (1) ATE286897T1 (enExample)
AU (1) AU2002224885A1 (enExample)
DE (1) DE60108420T2 (enExample)
ES (1) ES2234929T3 (enExample)
WO (1) WO2002044172A1 (enExample)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100448874C (zh) 2001-05-05 2009-01-07 史密斯克莱·比奇曼公司 N-芳酰基环胺
GB0115862D0 (en) * 2001-06-28 2001-08-22 Smithkline Beecham Plc Compounds
GB0124463D0 (en) * 2001-10-11 2001-12-05 Smithkline Beecham Plc Compounds
GB0127145D0 (en) * 2001-11-10 2002-01-02 Smithkline Beecham Compounds
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds
RU2005103398A (ru) * 2002-07-09 2006-06-27 Актелион Фармасьютикалз Лтд. (Ch) Производные 7,8,9,10-тетрагидро-6h-азепино-, 6,7,8,9-тетрагидропиридо-и 2,3-дигидро-2h-пирроло-[2,1-b]-хиназолинона
AU2003262516A1 (en) * 2002-09-18 2004-04-08 Glaxo Group Limited N-aroyl cyclic amines as orexin receptor antagonists
AU2003294671A1 (en) 2002-10-11 2004-05-04 Actelion Pharmaceuticals Ltd. Sulfonylamino-acetic derivatives and their use as orexin receptor antagonists
GB0225944D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
GB0225938D0 (en) * 2002-11-06 2002-12-11 Glaxo Group Ltd Novel compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN1780820A (zh) 2003-04-28 2006-05-31 埃科特莱茵药品有限公司 作为阿立新受体拮抗剂的喹喔啉－3－酮衍生物
SI1751111T1 (sl) 2004-03-01 2015-04-30 Actelion Pharmaceuticals Ltd. Substituirani 1,2,3,4-tetrahidroizokinolinski derivati
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
WO2006081522A2 (en) * 2005-01-26 2006-08-03 The Regents Of The Unversity Of California Modulation of nmda receptor currents via orexin receptor and/or crf receptor
US7501395B2 (en) 2005-04-25 2009-03-10 Eisai R & D Management Co., Ltd. Method of screening for antianxiety drugs
US20080267888A1 (en) * 2005-05-26 2008-10-30 Pandey Surendrakumar Satyanara Heterocyclic Derivatives
WO2007136790A2 (en) * 2006-05-18 2007-11-29 Mannkind Corporation Intracellular kinase inhibitors
JP2009543785A (ja) 2006-07-14 2009-12-10 メルク エンド カムパニー インコーポレーテッド 架橋ジアゼパンオレキシン受容体アンタゴニスト
CA2662612A1 (en) * 2006-09-29 2008-04-03 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.1.0]hexane derivatives
WO2008065626A2 (en) 2006-12-01 2008-06-05 Actelion Pharmaceuticals Ltd 3-heteroaryl (amino or amido)-1- (biphenyl or phenylthiazolyl) carbonylpiperidine derivativesas orexin receptor inhibitors
PE20081229A1 (es) 2006-12-01 2008-08-28 Merck & Co Inc Antagonistas de receptor de orexina de diazepam sustituido
CL2007003827A1 (es) 2006-12-28 2008-09-26 Actelion Pharmaceuticals Ltd Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras.
CL2008000836A1 (es) * 2007-03-26 2008-11-07 Actelion Pharmaceuticals Ltd Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras.
CA2688776A1 (en) 2007-05-18 2008-11-27 Merck & Co., Inc. Oxo bridged diazepan orexin receptor antagonists
WO2008150364A1 (en) 2007-05-23 2008-12-11 Merck & Co., Inc. Cyclopropyl pyrrolidine orexin receptor antagonists
AU2008257411B2 (en) 2007-05-23 2012-04-26 Merck Sharp & Dohme Corp. Pyridyl piperidine orexin receptor antagonists
DK2170930T3 (da) 2007-06-04 2012-11-05 Synergy Pharmaceuticals Inc Agonister af guanylatcyclase, anvendelige til behandlingen af gastrointestinale sygdomme, inflammation, cancer og andre sygdomme
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
AU2008272449A1 (en) * 2007-07-03 2009-01-08 Actelion Pharmaceuticals Ltd 3-aza-bicyclo[3.3.0]octane compounds
WO2009016564A2 (en) * 2007-07-27 2009-02-05 Actelion Pharmaceuticals Ltd 2-aza-bicyclo[3.3.0]octane derivatives
AR067665A1 (es) 2007-07-27 2009-10-21 Actelion Pharmaceuticals Ltd Derivados de trans-3- aza-biciclo ( 3.1.0) hexano
WO2009040730A2 (en) * 2007-09-24 2009-04-02 Actelion Pharmaceuticals Ltd Pyrrolidines and piperidines as orexin receptor antagonists
CN101965343A (zh) 2008-02-21 2011-02-02 埃科特莱茵药品有限公司 2-氮杂-双环[2.2.1]庚烷衍生物
KR20100135962A (ko) * 2008-04-30 2010-12-27 액테리온 파마슈티칼 리미티드 피페리딘 및 피롤리딘 화합물
WO2010004507A1 (en) * 2008-07-07 2010-01-14 Actelion Pharmaceuticals Ltd Thiazolidine compounds as orexin receptor antagonists
CA2730603C (en) 2008-07-16 2019-09-24 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
US8329914B2 (en) 2008-10-31 2012-12-11 Merck Sharp & Dohme Corp Cyclic benzimidazole derivatives useful as anti-diabetic agents
CN102300858A (zh) 2008-12-02 2011-12-28 葛兰素集团有限公司 N-{[(1r,4s,6r)-3-(2-吡啶基羰基)-3-氮杂双环[4.1.0]庚-4-基]甲基}-2-杂芳基胺衍生物及其用途
GB0823467D0 (en) 2008-12-23 2009-01-28 Glaxo Group Ltd Novel Compounds
JP2012524760A (ja) 2009-04-24 2012-10-18 グラクソ グループ リミテッド オレキシンアンタゴニストとして使用される３−アザビシクロ［４．１．０］ヘプタン
JP2013502447A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体
JP2013502448A (ja) 2009-08-24 2013-01-24 グラクソ グループ リミテッド オレキシンアンタゴニストとして用いられるピペリジン誘導体
JP2013520502A (ja) 2010-02-25 2013-06-06 メルク・シャープ・エンド・ドーム・コーポレイション 有用な抗糖尿病薬である新規な環状ベンズイミダゾール誘導体
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012089606A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists
WO2012089607A1 (en) 2010-12-28 2012-07-05 Glaxo Group Limited Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
AR088352A1 (es) 2011-10-19 2014-05-28 Merck Sharp & Dohme Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina
BR112014019426A8 (pt) 2012-02-07 2017-07-11 Eolas Therapeutics Inc Prolinas/ piperidinas substituídas como antagonistas do receptor de orexina
US9440982B2 (en) 2012-02-07 2016-09-13 Eolas Therapeutics, Inc. Substituted prolines/piperidines as orexin receptor antagonists
AU2013273222B2 (en) 2012-06-04 2017-11-02 Idorsia Pharmaceuticals Ltd Benzimidazole-proline derivatives
CA2880901A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
JP6244365B2 (ja) 2012-10-10 2017-12-06 アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ ［オルトビ−（ヘテロ−）アリール］−［２−（メタビ−（ヘテロ−）アリール）−ピロリジン−１−イル］−メタノン誘導体であるオレキシン受容体アンタゴニスト
JP2016516004A (ja) 2013-02-22 2016-06-02 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． 抗糖尿病二環式化合物
CN105051040A (zh) 2013-03-12 2015-11-11 埃科特莱茵药品有限公司 作为食欲素受体拮抗剂的氮杂环丁烷酰胺衍生物
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
US9708367B2 (en) 2013-03-15 2017-07-18 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase and their uses
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
AU2014274812B2 (en) 2013-06-05 2018-09-27 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase C, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
LT3077389T (lt) 2013-12-03 2017-12-11 Idorsia Pharmaceuticals Ltd Kristalinė (s)-(2-(6-chlor-7-metil-1h-benzo[d]imidazol-2-il)-2-metilpirolidin-1-il)(5-metoksi-2-(2h-1,2,3-triazol-2-il)fenil)metanono forma ir jos panaudojimas kaip oreksino receptoriaus antagonisto
UA119151C2 (uk) 2013-12-03 2019-05-10 Ідорсія Фармасьютікалз Лтд КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА
EP3077391B1 (en) 2013-12-04 2018-08-15 Idorsia Pharmaceuticals Ltd Use of benzimidazole-proline derivatives
AR101558A1 (es) 2014-08-13 2016-12-28 Eolas Therapeutics Inc Difluoropirrolidinas como moduladores del receptor de orexina
US10894789B2 (en) 2016-02-12 2021-01-19 Astrazeneca Ab Halo-substituted piperidines as orexin receptor modulators
US20190151304A1 (en) 2016-05-10 2019-05-23 Inserm (Institut National De La Santé Et De La Rechercjae Médicale Methods and pharmaceutical compositions for the treatment of autoimmune inflammatory
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
WO2020007964A1 (en) 2018-07-05 2020-01-09 Idorsia Pharmaceuticals Ltd 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives
WO2020099511A1 (en) 2018-11-14 2020-05-22 Idorsia Pharmaceuticals Ltd Benzimidazole-2-methyl-morpholine derivatives
AU2020286381C1 (en) 2019-06-04 2025-07-10 Hager Biosciences, Llc Imidazolo derivatives, compositions and methods as orexin antagonists
AR129309A1 (es) 2022-05-13 2024-08-07 Idorsia Pharmaceuticals Ltd Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo
GB202311280D0 (en) * 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists
GB202311281D0 (en) * 2023-07-21 2023-09-06 Bial Portela & Ca Sa Orexin receptor antagonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3621775A1 (de) * 1986-03-13 1988-01-07 Thomae Gmbh Dr K Neue substituierte thiazole und oxazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
SK289787A3 (en) * 1986-04-30 1998-06-03 Dainippon Pharmaceutical Co Substituted n-£(2-morpholinyl)alkyl|benzamide derivative, method of producing the same and a pharmaceutical composition on its base
GB8813714D0 (en) * 1988-06-09 1988-07-13 Glaxo Group Ltd Chemical compounds
US5719147A (en) * 1992-06-29 1998-02-17 Merck & Co., Inc. Morpholine and thiomorpholine tachykinin receptor antagonists
AU2804400A (en) 1999-02-12 2000-08-29 Smithkline Beecham Plc Phenyl urea and phenyl thiourea derivatives as orexin receptor antagonists
ES2231158T3 (es) * 1999-02-12 2005-05-16 Smithkline Beecham Plc Derivados y fenil urea y fenil tiourea.
FR2791346B3 (fr) * 1999-03-25 2001-04-27 Sanofi Sa Nouveaux derives de morpholine, procede pour leur preparation et compositions pharmaceutiques les contenant
US6635661B2 (en) * 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
US6677332B1 (en) * 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
ES2234840T3 (es) * 2000-03-14 2005-07-01 Actelion Pharmaceuticals Ltd. Derivados de 1,2,3,4- tetrahidroisoquinolina.
US6677354B2 (en) * 2000-06-16 2004-01-13 Smithkline Beecham P.L.C. Piperdines for use as orexin receptor antagonists
AR035205A1 (es) * 2000-09-29 2004-05-05 Glaxo Group Ltd Compuestos utiles en el tratamiento de enfermedades inflamatorias, proceso para su preparacion, intermediarios y composiciones farmaceuticas
GB0130335D0 (en) * 2001-12-19 2002-02-06 Smithkline Beecham Plc Compounds

Also Published As

Publication number Publication date
AU2002224885A1 (en) 2002-06-11
DE60108420D1 (en) 2005-02-17
DE60108420T2 (de) 2005-12-22
ES2234929T3 (es) 2005-07-01
JP2004521087A (ja) 2004-07-15
EP1353918A1 (en) 2003-10-22
US20040058921A1 (en) 2004-03-25
EP1353918B1 (en) 2005-01-12
JP4246490B2 (ja) 2009-04-02
WO2002044172A1 (en) 2002-06-06
US6943160B2 (en) 2005-09-13

Similar Documents

Publication Publication Date Title
ATE286897T1 (de) Morpholinderivate als antagonisten an orexinrezeptoren
ATE312811T1 (de) Benzamidinderivate als antagonisten von orexinrezeptoren
DE60222396D1 (de) N-(2-arylethyl) benzylamine als 5-ht6 rezeptor-antagoniste
SE0000540D0 (sv) New compounds
DE60139021D1 (de) Piperazinylpyrazinverbindungen als antagonisten des serotonin-5-ht2-rezeptors
DE60309481D1 (de) Cyclische n-aroylamine als orexinrezeptorantagonisten
CY1111317T1 (el) Παραγωγα 4-φαινυλοπυριδινης και χρηση αυτων ως ανταγωνιστων υποδοχεων της νκ-1
ATE346070T1 (de) Purinderivate als kinaseinhibitoren
DE69910831D1 (de) Epothilonderivate und ihre verwendung als antitumormittel
ATE303399T1 (de) Steroide als agonisten für fxr
CY1105386T1 (el) Βενζοϋλοσουλφοναμιδια και σουλφονυλβενζαμιδινες για χρηση σαν παραγοντες κατα του ογκου
PT1513826E (pt) Novos derivados de indolilpiperidina como agentes anti-histaminicos e antialergicos potentes
UA88012C2 (uk) Похідні хіназоліндіону як інгібітори parp
DE60117814D1 (de) Nicht-imidazol aryloxyalkylamine als h3 rezeptor liganden
DE60228487D1 (de) Ethylenediaminderivate und ihre verwendung als orexinrezeptorantagonisten
NO20042534L (no) Forbedringer vedrorende optiske lysgjoringsmidler
BR0206595A (pt) Composto, composição farmacêutica, e uso de um composto
DE60112306D1 (de) Kondensierte pyrazindionderivate als pde5 inhibitore
PT1181294E (pt) Novos derivados e analogos da galantamina
MXPA05009988A (es) Derivados de 6-sulfonamida quinolina y cromeno como antagonistas de los receptores de androgenos.
ATE333457T1 (de) Zyklische gmp-spezifische phosphodiesteraseinhibitoren
DE60041001D1 (de) Substituierte homopiperidylbenzimidazolanaloga als fundusrelaxantien
BRPI0416678A (pt) pirazolpirimidinas
PT1497292E (pt) Derivados de azaindolilpiperidina como agentes anti-histaminicos e antialergicos
PA8557201A1 (es) Compuestos basicos lineales que tienen actividad antagonista de nk-2 y su formulaciones

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties